Rivia Raises €3M in Seed Funding to Enhance AI-Driven Clinical Trial Data Platform
Rivia is dedicated to transforming the way biotech companies manage and analyze clinical trial data.
Company Name: Rivia
Location: Zurich, Switzerland
Sector: Healthcare Technology, Artificial Intelligence
Funding Details: Raised €3M in Seed funding. The round was led by Speedinvest, with participation from Amino Collective and Nina Capital.
Purpose of Investment: To hire new teams across engineering and client services, advance product development, and strengthen its position as the unified data platform for biopharma clinical trials.
Leadership: Led by CEO Erik Scalfaro and CTO Thiago Kieliger.
Product: Rivia specializes in AI-driven analytics and clinical trial data infrastructure for Biotechs. The platform simplifies the acquisition and understanding of clinical trial data through interactive analytics and AI-driven insights, aiming to enhance the efficiency and effectiveness of clinical trials.
About Company: Rivia is dedicated to transforming the way biotech companies manage and analyze clinical trial data. By providing a unified platform that offers advanced data processing and analytics, Rivia helps clients in Europe and the US streamline their clinical trial processes, making data more accessible and actionable. With this new funding, Rivia is poised to expand its capabilities and further its impact in the biopharma industry.
